What is the recommended loratadine dose for children aged 2–5 years and for those ≥6 years, and are there any dosing adjustments for infants under 2 years or for hepatic/renal impairment?

Loratadine Dosing in Pediatric Patients

For children aged 2–5 years, administer loratadine 5 mg (1 teaspoonful) once daily; for children ≥6 years, administer 10 mg (2 teaspoonfuls) once daily. 1

Standard Pediatric Dosing by Age

Children 2 to Under 6 Years

• Dose: 5 mg (1 teaspoonful of syrup) once daily 1
• Maximum: Do not exceed 5 mg in 24 hours 1
• Formulation: Loratadine syrup 1 mg/mL (5 mg per teaspoonful) 2

Children ≥6 Years and Adolescents

• Dose: 10 mg (2 teaspoonfuls of syrup or one 10 mg tablet) once daily 1
• Maximum: Do not exceed 10 mg in 24 hours 1

Infants Under 2 Years

• Loratadine is not FDA-approved for children under 2 years of age 1
• Consult a physician before use in this age group 1

Pharmacokinetic Rationale for Dosing

• The 5 mg dose in children aged 2–5 years provides plasma exposure similar to the 10 mg adult dose, with peak plasma concentrations of loratadine at 7.78 ng/mL occurring approximately 1.2 hours post-dose 2
• The active metabolite desloratadine reaches peak concentration of 5.09 ng/mL at 2.3 hours, with an AUC of 87.2 ng·h/mL 2
• Duration of action is at least 24 hours, supporting once-daily dosing 3
• Onset of action occurs within 1 hour of administration 3

Dosing Adjustments for Special Populations

Hepatic Impairment

• Consult a physician before administering loratadine to children with liver disease 1
• Adult data suggest starting with alternate-day dosing (10 mg every other day) for significant hepatic dysfunction, though pediatric-specific guidance is limited 1

Renal Impairment

• Consult a physician before administering loratadine to children with kidney disease 1
• Dose adjustment may be necessary based on creatinine clearance, though specific pediatric recommendations are not established in the FDA label 1

Safety and Tolerability Profile

• Loratadine 5 mg once daily for 15 days in children aged 2–5 years showed adverse event rates comparable to placebo (7/55 vs 6/56) 2
• No electrocardiographic changes were observed compared to placebo in pediatric studies 2
• A single 300 mg ingestion (60-fold overdose) in a 6-year-old resulted only in minor elevation of blood pressure and heart rate with supportive care 4
• No clinically meaningful changes in vital signs, laboratory values, or physical examination findings occurred in controlled trials 2

Clinical Considerations and Common Pitfalls

Advantages Over First-Generation Antihistamines

• Loratadine is strongly preferred over diphenhydramine in all pediatric age groups due to superior safety 5
• Second-generation antihistamines like loratadine have minimal sedation and lack the central nervous system toxicity associated with first-generation agents 5
• Between 1969–2006,33 deaths in children under 6 years were attributed to diphenhydramine, whereas loratadine has an excellent safety record 5

Administration Guidelines

• Loratadine may be administered without regard to meals 3
• Use the enclosed dosing cup to ensure accurate measurement 1
• Do not use OTC cough-and-cold combination products containing loratadine in children under 6 years due to overdose risk from multiple active ingredients 5

When to Avoid or Seek Medical Advice

• Do not use loratadine to induce sleep; this is explicitly contraindicated per FDA labeling 5
• For severe allergic reactions or anaphylaxis, epinephrine is the only first-line treatment—loratadine is not appropriate for emergency management 5
• Refer to a pediatric allergist for recurrent symptoms requiring ongoing antihistamine therapy 5